This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

NeoDynamics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

NeoDynamics şirketinin kazançları yıllık ortalama -32.7% oranında azalırken, Medical Equipment sektörünün kazançları yıllık 21.2% oranında artan oldu. Gelirler yıllık ortalama 62.5% oranında azalan oldu.

Anahtar bilgiler

-32.7%

Kazanç büyüme oranı

26.3%

EPS büyüme oranı

Medical Equipment Sektör Büyümesi	6.2%
Gelir büyüme oranı	-62.5%
Özkaynak getirisi	-182.3%
Net Marj	-11,509.6%
Sonraki Kazanç Güncellemesi	20 Aug 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Is NeoDynamics (NGM:NEOD) In A Good Position To Invest In Growth?

Mar 18

NeoDynamics AB (publ) (NGM:NEOD) Insiders Increased Their Holdings

Dec 03

Gelir ve Gider Dağılımı

NeoDynamics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

OM:NEOD Gelir, gider ve kazançlar (SEK Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
31 Mar 24	1	-87	66
31 Dec 23	1	-93	72
30 Sep 23	1	-101	78
30 Jun 23	0	-91	70
31 Mar 23	0	-82	62
31 Dec 22	0	-75	55
30 Sep 22	1	-68	49
30 Jun 22	1	-66	48
31 Mar 22	2	-67	47
31 Dec 21	2	-69	47
30 Sep 21	4	-60	46
30 Jun 21	6	-54	47
31 Mar 21	11	-41	47
31 Dec 20	17	-31	47
30 Sep 20	20	-26	35
30 Jun 20	22	-24	28
31 Mar 20	23	-23	19
31 Dec 19	22	-19	9
30 Sep 19	25	-21	10
30 Jun 19	24	-21	9
31 Mar 19	26	-20	9
31 Dec 18	25	-18	7
31 Dec 17	11	-7	5
31 Dec 16	8	-8	4

Kaliteli Kazançlar: NEOD şu anda kârlı değil.

Büyüyen Kar Marjı: NEOD şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: NEOD kârlı değildir ve zararlar son 5 yılda yılda 32.7% oranında artmıştır.

Büyüme Hızlandırma: NEOD 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: NEOD kârlı olmadığından, geçmiş yıl kazanç büyümesinin Medical Equipment sektörüyle ( 28.2% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: NEOD hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -182.31% ) sahiptir.

This company listing is no longer active

NeoDynamics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

First quarter 2024 earnings released: kr0.058 loss per share (vs kr19.28 loss in 1Q 2023)

Full year 2023 earnings released: kr30.21 loss per share (vs kr62.00 loss in FY 2022)

NeoDynamics AB (publ) to Report Nine Months, 2024 Results on Nov 19, 2024

Second quarter 2023 earnings released: kr0.22 loss per share (vs kr0.17 loss in 2Q 2022)

Full year 2022 earnings released: kr0.76 loss per share (vs kr1.14 loss in FY 2021)

NeoDynamics AB (publ) to Report Fiscal Year 2023 Results on Feb 16, 2024

Recent updates

Nasdaq Stockholm AB Decides the Shares in NeoDynamics Shall Be Given Observation Status

First quarter 2024 earnings released: kr0.058 loss per share (vs kr19.28 loss in 1Q 2023)

Full year 2023 earnings released: kr30.21 loss per share (vs kr62.00 loss in FY 2022)

NeoDynamics AB (publ) to Report Nine Months, 2024 Results on Nov 19, 2024

Insufficient new directors

NeoDynamics AB (publ) Announces CFO Aaron Wong to Leave by End of May 2024

Neodynamics Launches Device Registry in Germany, Cost-Effective Collection of Real-World Data

New major risk - Shareholder dilution

NeoDynamics AB (publ) has completed a Composite Units Offering in the amount of SEK 72.30071 million.

Second quarter 2023 earnings released: kr0.22 loss per share (vs kr0.17 loss in 2Q 2022)

Neodynamics AB Presents Results of Pulse Study At the Annual Congress of the German Society of Senology, Munich

NeoDynamics AB Presents Final Data Set from NeoDynamics' Pulse Study Presented at the SBI Breast Imaging Symposium

Full year 2022 earnings released: kr0.76 loss per share (vs kr1.14 loss in FY 2021)

NeoDynamics AB (publ) to Report Fiscal Year 2023 Results on Feb 16, 2024

NeoDynamics Announces Changes to Board of Directors

NeoDynamics Appoints Matthew Colpoys, to Lead US Operations

Third quarter 2022 earnings released: kr0.12 loss per share (vs kr0.22 loss in 3Q 2021)

Price target decreased to kr1.10

NeoDynamics AB (publ) Appoints Brendan Carney as National Sales Director

Neodynamics AB (Publ) Launches Neonavia Biopsy System Configured with Its Flexipulse Probe in the United States to Support the Diagnosis of Cancer

NeoDynamics AB (publ) to Report Q3, 2022 Results on Nov 17, 2022

NeoDynamics Receives Approval for Its Innovative Pulse Biopsy System Neonavia® from the US Food and Drug Administration, FDA

Second quarter 2022 earnings released: kr0.17 loss per share (vs kr0.30 loss in 2Q 2021)

Neodynamics AB (Publ) Receives Ethical Approval for German Device Registry

Gryningskust Holding AB acquired additional 14.0 % minority stake in NeoDynamics AB (publ) (OM:NEOD).

NeoDynamics AB (publ) Announces Update on the FDA approval process for NeoNavia

First quarter 2022 earnings released: kr0.28 loss per share (vs kr0.29 loss in 1Q 2021)

NeoDynamics AB (publ) to Report Q1, 2022 Results on May 12, 2022

NeoDynamics Files a Registration Application for Its Innovative Pulse Biopsy System NeoNavia in the U.S

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

NeoDynamics AB (publ) to Report Fiscal Year 2021 Results on Feb 16, 2022

NeoDynamics AB to Present Results from the Pulse Study Illustrating the Benefits of the Novel Biopsy Device NeoNavia in Challenging Axillary Lymph Nodes, At the SBI/ACR Breast Imaging Symposium in Savannah, Georgia

Third quarter 2021 earnings released: kr0.22 loss per share (vs kr0.19 loss in 3Q 2020)

Neodynamics Grants A U.S. Patent for Its Biopsy Needle

Second quarter 2021 earnings released: kr0.30 loss per share (vs kr0.18 loss in 2Q 2020)

CFO & Head of Investor Relations Jorgen Vrenning has left the company

First quarter 2021 earnings released: kr0.29 loss per share (vs kr0.41 loss in 1Q 2020)

NeoDynamics AB Presents an Abstract on Pulse Biopsy Data for NeoNavia at the UK Association of Breast Surgeons Conference 2021

Is NeoDynamics (NGM:NEOD) In A Good Position To Invest In Growth?

New 90-day low: kr3.00

Full year 2020 earnings released: kr0.52 loss per share (vs kr1.24 loss in FY 2019)

New 90-day low: kr3.38

New 90-day low: kr3.60

NeoDynamics Will Be Granted Another European Patent for Its Pulse Biopsy Tools

New 90-day low: kr3.75

Insider recently sold kr423k worth of stock

NeoDynamics AB (publ) (NGM:NEOD) Insiders Increased Their Holdings

Third quarter 2020 earnings released: kr0.19 loss per share

NeoDynamics AB (Publ) Wins First UK Order of Pulse Biopsy System Neonavia

NeoDynamics AB (publ) Enters A Scientific Partnership to Evaluate Its Technology Platform in Osteoarthritis

NeoDynamics AB (publ) Announces Executive Changes

NeoDynamics AB (publ) Ready to Launch the New Pulse Biopsy System NeoNavia

New 90-day high - kr3.49

Earnings released

New 90-day high - kr3.37

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin